Trial · NCT00402714
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
NCT00402714, Phase 2, Completed, Yale University; results first posted 2017-01-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies. Trials, record NCT00402714. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00402714
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
- NCT number
- NCT00402714
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Hematologic Malignancies
- Interventions
- extracorporeal photopheresis, Pentostatin, Total Body Irradiation, Pentostatin, Total Body Irradiation
- First posted
- 2006-11-22
- Last updated
- 2017-01-18
- Results first posted
- 2017-01-18
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis | Day +100 following allogeneic stem cell transplant | |
| Secondary | Overall Survival | 2 years following stem cell transplant |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis | Day +100 following allogeneic stem cell transplant | participants | NUMBER | |
| SECONDARY | Overall Survival | 2 years following stem cell transplant | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis | 1 ECP and Pent/TBI | 1 | participants | ||
| Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis | 2 Pent/TBI | 8 | participants | ||
| Overall Survival | ECP Pento TBI | 2 | participants | ||
| Overall Survival | Pento TBI | 5 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ECP/Pent | 3 | |
| Overall Study | STARTED | Pent | 11 | |
| Overall Study | COMPLETED | ECP/Pent | 3 | |
| Overall Study | COMPLETED | Pent | 11 | |
| Overall Study | NOT COMPLETED | ECP/Pent | 0 | |
| Overall Study | NOT COMPLETED | Pent | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | skin infection | Skin and subcutaneous tissue disorders | ECP/Pent | 0 | 3 | 0 |
| other | skin infection | Skin and subcutaneous tissue disorders | Pent | 1 | 11 | 1 |
| serious | ards | Respiratory, thoracic and mediastinal disorders | ECP/Pent | 1 | 3 | 1 |
| serious | ards | Respiratory, thoracic and mediastinal disorders | Pent | 3 | 11 | 3 |
| serious | dvt | Vascular disorders | ECP/Pent | 0 | 3 | 0 |
| serious | dvt | Vascular disorders | Pent | 3 | 11 | 11 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ECP/Pent | ||
| Total, all-cause mortality | Pent | ||
| Total, other adverse events | ECP/Pent | 0 | 3 |
| Total, other adverse events | Pent | 1 | 11 |
| Total, serious adverse events | ECP/Pent | 1 | 3 |
| Total, serious adverse events | Pent | 4 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| ECP Pento TBI vs Pento TBI: Overall Survival | Trial comparisons |
| 1 ECP and Pent/TBI vs 2 Pent/TBI: Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis | Trial comparisons |
| ECP/Pent vs Pent: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00402714
GET https://conductscience.org/api/trials/v1/NCT00402714/registered